^
    Back
    Association details:
    Biomarker:CEACAM5 expression
    Cancer:Gastric Cancer
    Drug:tusamitamab ravtansine (SAR408701) (Microtubule inhibitor, CEACAM5-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

    Excerpt:
    ...- Expression of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) will be assessed centrally using the most recent archival tumor tissue (or, if...
    Trial ID:
    TusaRav-QT
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701

    Excerpt:
    ...Intratumoral tusamitamab ravtansine concentration`Incidence of grade 3 or 4 adverse events`Response to treatment`CEACAM5 expression`RNA expression levels`circulating CEA levels`tumor genomic features`Maximal plasma concentration`AUCinf`AUClast`AUCt`Thalf`systemic tusamitamab ravtansine concentration`Volume of distribution`concentration DM4 metabolites: Lys-SPDB-DM4, Me-Dm4`features in tumor micro-environment...
    Trial ID:
    INTRUSION
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Evaluation of SAR408701 in Patients With Advanced Solid Tumors

    Excerpt:
    ...Patient must consent to a baseline biopsy for retrospective confirmation of tumor CEACAM5 expression, except if NSCLC or SCLC without lesion amenable to biopsy....
    Trial ID:
    CEACAM5
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res
    Title:

    Abstract 4151: Anti-CEACAM5 immune stimulant TLR7/8 agonist antibody drug conjugate is a potent myeloid cell activator for the treatment of CEACAM5-expressing tumors

    Published date:
    04/04/2023
    Excerpt:
    In co-culture of human blood cells and human CEACAM5+ gastric cancer cells, it was shown to induce phagocytosis activity, associated with increased activation/maturation of both monocytes and dendritic cells. Tusamitamab R848 ADC evaluated in vivo in CEACAM5+ pancreatic human tumor model, HPAFII, leads to robust antitumor activity with complete regressions (CR) after single administration at 5 mg/kg....Based on preclinical in vitro and in vivo data, the tusamitamab R848 ADC is an innovative ADC approach with the potential to eradicate CEACAM5+ tumors in patients.
    DOI:
    https://doi.org/10.1158/1538-7445.AM2023-4151